Follow
Scott Rodig
Scott Rodig
Professor of Pathology, Brigham & Women's Hospital
Verified email at bwh.harvard.edu
Title
Cited by
Cited by
Year
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma
SM Ansell, AM Lesokhin, I Borrello, A Halwani, EC Scott, M Gutierrez, ...
New England Journal of Medicine 372 (4), 311-319, 2015
33092015
Clinical features and outcome of patients with non–small-cell lung cancer who harbor EML4-ALK
AT Shaw, BY Yeap, M Mino-Kenudson, SR Digumarthy, DB Costa, ...
Journal of clinical oncology 27 (26), 4247, 2009
21542009
Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK–STAT signaling pathway
MA Meraz, JM White, KCF Sheehan, EA Bach, SJ Rodig, AS Dighe, ...
Cell 84 (3), 431-442, 1996
19631996
An immunogenic personal neoantigen vaccine for patients with melanoma
PA Ott, Z Hu, DB Keskin, SA Shukla, J Sun, DJ Bozym, W Zhang, A Luoma, ...
Nature 547 (7662), 217-221, 2017
17682017
Adaptive immunity maintains occult cancer in an equilibrium state
CM Koebel, W Vermi, JB Swann, N Zerafa, SJ Rodig, LJ Old, MJ Smyth, ...
Nature 450 (7171), 903-907, 2007
15542007
MYD88 L265P somatic mutation in Waldenström's macroglobulinemia
SP Treon, L Xu, G Yang, Y Zhou, X Liu, Y Cao, P Sheehy, RJ Manning, ...
New England Journal of Medicine 367 (9), 826-833, 2012
12362012
Comprehensive analyses of tumor immunity: implications for cancer immunotherapy
B Li, E Severson, JC Pignon, H Zhao, T Li, J Novak, P Jiang, H Shen, ...
Genome biology 17 (1), 1-16, 2016
11532016
Integrative analysis reveals selective 9p24. 1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and …
MR Green, S Monti, SJ Rodig, P Juszczynski, T Currie, E O'Donnell, ...
Blood, The Journal of the American Society of Hematology 116 (17), 3268-3277, 2010
11332010
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors
EA Akbay, S Koyama, J Carretero, A Altabef, JH Tchaicha, ...
Cancer discovery 3 (12), 1355-1363, 2013
10552013
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
S Koyama, EA Akbay, YY Li, GS Herter-Sprie, KA Buczkowski, ...
Nature communications 7 (1), 1-9, 2016
10442016
Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses
SJ Rodig, MA Meraz, JM White, PA Lampe, JK Riley, CD Arthur, KL King, ...
Cell 93 (3), 373-383, 1998
10241998
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
B Chapuy, C Stewart, AJ Dunford, J Kim, A Kamburov, RA Redd, ...
Nature medicine 24 (5), 679-690, 2018
8662018
Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study
AM Lesokhin, SM Ansell, P Armand, EC Scott, A Halwani, M Gutierrez, ...
Journal of clinical oncology 34 (23), 2698, 2016
8512016
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
A Younes, A Santoro, M Shipp, PL Zinzani, JM Timmerman, S Ansell, ...
The lancet oncology 17 (9), 1283-1294, 2016
8372016
Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor
JE Butrynski, DR D'Adamo, JL Hornick, P Dal Cin, CR Antonescu, ...
New England Journal of Medicine 363 (18), 1727-1733, 2010
8012010
PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies
BJ Chen, B Chapuy, J Ouyang, HH Sun, MGM Roemer, ML Xu, H Yu, ...
Clinical cancer research 19 (13), 3462-3473, 2013
7942013
Ibrutinib in previously treated Waldenström’s macroglobulinemia
SP Treon, CK Tripsas, K Meid, D Warren, G Varma, R Green, ...
New England Journal of Medicine 372 (15), 1430-1440, 2015
7802015
Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells
KP Koh, A Yabuuchi, S Rao, Y Huang, K Cunniff, J Nardone, A Laiho, ...
Cell stem cell 8 (2), 200-213, 2011
7672011
Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population
SJ Rodig, M Mino-Kenudson, S Dacic, BY Yeap, A Shaw, JA Barletta, ...
Clinical cancer research 15 (16), 5216-5223, 2009
7672009
The biology and treatment of EML4-ALK non-small cell lung cancer
T Sasaki, SJ Rodig, LR Chirieac, PA Jänne
European journal of cancer 46 (10), 1773-1780, 2010
6912010
The system can't perform the operation now. Try again later.
Articles 1–20